INTERVIEWS
BRÈVES
VIALE-A : la messe est dite
D’après la communication orale de DiNardo C al. A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy-VIALE-A. Abstract LB2601.
Moins d’affinité pour plus d’efficacité ?
D’après la communication orale de Roddie C et al. ALLCAR19: updated data using AUTO1, a novel fast-off rate CD19 CAR in relapsed/refractory B-acute lymphoblastic leukaemia. Abstract S119.
Prise en charge du lymphome de Hodgkin localisé et étendu : la vision allemande
D’après les communications orales de :
– Kreissl S et al. PET guided treatment in patients with advanced-stage Hodgkin Lymphoma: follow-up analysis of PET-2-negative patients in the HD18 trial by the German Hodgkin Study Group. Abstract S222.
– Eichenauer DA et al. PET guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma; an analysis from the German Hodgkin Study Group. Abstract S220.
– Borchmann P et al. Positron emission tomography guided omission of radiotherapy in early stage unfavorable Hodgkin Lymphoma: final results of the international randomized phase III HD17 trial by the GHSG. Abstract S101.
Le glofitamab, un nouvel anticorps bispécifique dans les lymphomes non hodgkiniens
D’après la communication orale de Dickinson M et al. CD20-TCB in relapsed or refractory Non Hodgkin Lymphoma: durable complete responses and manageable safety observed at clinically relevant doses in phase I dose escalation. Abstract S241
CAPTIVATE : MRD après 1 an de combinaison ibrutinib + vénétoclax
D’après la communication orale de Siddiqi T et al. First line ibrutinib + venetoclax for patients with CLL/SLL: efficacy and safety results from captivate MRD cohort. Abstract S158.
Une triplette efficace dans la LLC avec délétion 17p en première ligne
D’après la communication orale de Huber H et al. CLL2-GIVe, a prospective, open label, multicenter phase II trial of obinutuzumab Ibrutinib et venetoclax in untreated patients with del 17p deletion TP53 mutation. Abstract S157.
